论文部分内容阅读
[目的]研究含紫杉醇(PTX)持续静脉滴注方案二线治疗晚期食管癌的疗效和毒性。[方法]26例晚期食管鳞癌患者应用含低剂量PTX持续静脉输注联合方案化疗:PTX20mg/m2,civ,16h,d1～3,d8～9;DDP3.75mg/m2,iv,d1～4,d8～11;5-Fu375mg/m2,civ,24h,d1～5,d8～12;叶酸60mg,po,d1～5,d8～12;21d为1个周期,至少应用2个周期。[结果]23例完成2个周期治疗者可评价疗效,CR1例,PR9例,SD10例,PD3例,有效率为43.5%,中位疾病进展时间(TTP)5.1个月。主要毒副反应为骨髓抑制和脱发,其他毒副反应较轻。[结论]低剂量PTX持续静脉输注联合方案治疗晚期食管鳞癌安全有效。
[Objective] To study the efficacy and toxicity of second-line paclitaxel (PTX) continuous intravenous infusion regimen in the treatment of advanced esophageal cancer. [Methods] Twenty-six patients with advanced esophageal squamous cell carcinoma were treated with PTX 20mg / m2, civ, 16h, d1-3, d8-9, DDP3.75mg / m2, iv, d1-4 , d8 ~ 11; 5-Fu375mg / m2, civ, 24h, d1 ~ 5, d8 ~ 12; folic acid 60mg, po, d1 ~ 5, d8 ~ 12; 21d for a period of at least two cycles. [Results] Twenty-three patients who completed 2 cycles of treatment could evaluate the efficacy. CR1, PR9, SD10 and PD3 had an effective rate of 43.5% and a median time to progression (TTP) of 5.1 months. The main side effects of myelosuppression and hair loss, other toxic side effects lighter. [Conclusion] The low dose PTX continuous intravenous infusion regimen is safe and effective in the treatment of advanced esophageal squamous cell carcinoma.